These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35630029)

  • 21. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
    Schaeffer MJ; Callahan BL;
    J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.
    Chaudhry A; Houlden H; Rizig M
    J Neurol Sci; 2020 Aug; 415():116886. PubMed ID: 32428759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.
    Lerche S; Machetanz G; Wurster I; Roeben B; Zimmermann M; Pilotto A; Preische O; Stransky E; Deuschle C; Hauser AK; Schulte C; Lachmann I; Waniek K; Gasser T; Berg D; Maetzler W; Brockmann K
    Mov Disord; 2019 Jul; 34(7):1069-1073. PubMed ID: 31189032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia.
    Funnell C; Feldman HH; Mackenzie IRA; DeMarco ML
    Alzheimer Dis Assoc Disord; 2020; 34(4):357-359. PubMed ID: 33215886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
    Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
    J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.
    Vanderstichele H; De Vreese K; Blennow K; Andreasen N; Sindic C; Ivanoiu A; Hampel H; Bürger K; Parnetti L; Lanari A; Padovani A; DiLuca M; Bläser M; Olsson AO; Pottel H; Hulstaert F; Vanmechelen E
    Clin Chem Lab Med; 2006; 44(12):1472-80. PubMed ID: 17163825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B; Bibl M; Wiltfang J; Steinacker P; Ciesielczyk B; Neubert K; Trenkwalder C; Otto M
    Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.
    Shi M; Tang L; Toledo JB; Ginghina C; Wang H; Aro P; Jensen PH; Weintraub D; Chen-Plotkin AS; Irwin DJ; Grossman M; McCluskey L; Elman LB; Wolk DA; Lee EB; Shaw LM; Trojanowski JQ; Zhang J
    Alzheimers Dement; 2018 Aug; 14(8):1052-1062. PubMed ID: 29604263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
    J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
    Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
    J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid in the dementias.
    Zetterberg H; Rohrer JD; Schott JM
    Handb Clin Neurol; 2017; 146():85-97. PubMed ID: 29110781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies.
    Bousiges O; Blanc F
    Clin Chim Acta; 2019 Mar; 490():222-228. PubMed ID: 30471248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.
    Llorens F; Schmitz M; Varges D; Kruse N; Gotzmann N; Gmitterová K; Mollenhauer B; Zerr I
    J Neurol; 2016 Nov; 263(11):2271-2277. PubMed ID: 27544498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.